Role of extracellular vesicles of different origins in the development and progression of hepatocellular carcinoma

Tingting SHI; Runbing ZHANG; Yang WU; Yani ZHANG; Lingling ZHU; Chun GAO; Jingjing JIANG; Xiaofeng ZHENG; Jiucong ZHANG

doi:10.12449/JCH240630

Volume 40 Issue 6

Jun. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(6): 1264-1268

PDF( 878 KB)

Role of extracellular vesicles of different origins in the development and progression of hepatocellular carcinoma

DOI: 10.12449/JCH240630

Tingting SHI^{1, 2},
Runbing ZHANG^{1, 2},
Yang WU^{1, 2},
Yani ZHANG^{1, 2},
Lingling ZHU^{1, 2},
Chun GAO^{1, 2},
Jingjing JIANG^{1, 2},
Xiaofeng ZHENG^{3
,
,
,},
Jiucong ZHANG^{1
,
,
,}

1.
Department of Gastroenterology，The 940 Hospital of Joint Logistic Support Force of PLA，Lanzhou 730050，China
2.
The First Clinical Medical College of Gansu University of Chinese Medicine，Lanzhou 730000，China
3.
Department of Gastroenterology，The Second Hospital of Lanzhou University，Lanzhou 730030，China

Research funding:

Central University Excellent Youth Team Cultivation Project (31920220065);

Gansu Clinical Medical Research Center for Non-infectious Liver Diseases (21JR7RA017);

Gansu Natural Science Foundation (22JR5RA1012);

Lanzhou Youth Science and Technology Talent Innovation Key Project (2023-2-29);

Gansu Youth Science and Technology Fund (23JRRA1673)

More Information

Corresponding author: ZHENG Xiaofeng， zhengxf19892013@126.com （ORCID： 0009-0002-9660-1224）; ZHANG Jiucong， zhangjiucong@163.com （ORCID： 0000-0003-4006-3033）
Received Date: 2024-01-09
Accepted Date: 2024-02-01
Published Date: 2024-06-25

Abstract

Abstract

Hepatocellular carcinoma （HCC） is the most common type of primary liver cancer and the third leading cause of cancer-related deaths， and it is a serious threat to human health and has become a clinical problem that needs to be solved urgently. Extracellular vesicles （EV） are membrane vesicles containing multiple components and play an important role in the development and progression of HCC. This article summarizes the effect of EVs of different origins on HCC and analyzes the mechanism of action of EV on HCC， so as to provide new perspectives for the diagnosis and treatment of HCC.
- Carcinoma， Hepatocellular,
- Extracellular Vesicles,
- Diagnosis

FullText(HTML)

References(34)

References

[1]	WANG H, YU L, HUANG P, et al. Tumor-associated exosomes are involved in hepatocellular carcinoma tumorigenesis, diagnosis, and treatment[J]. J Clin Transl Hepatol, 2022, 10( 3): 496- 508. DOI: 10.14218/JCTH.2021.00425.
[2]	FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391( 10127): 1301- 1314. DOI: 10.1016/s0140-6736(18)30010-2.
[3]	VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380( 15): 1450- 1462. DOI: 10.1056/nejmra1713263.
[4]	HADE MD, SUIRE CN, SUO ZC. Mesenchymal stem cell-derived exosomes: Applications in regenerative medicine[J]. Cells, 2021, 10( 8): 1959. DOI: 10.3390/cells10081959.
[5]	HADE MD, SUIRE CN, MOSSELL J, et al. Extracellular vesicles: Emerging frontiers in wound healing[J]. Med Res Rev, 2022, 42( 6): 2102- 2125. DOI: 10.1002/med.21918.
[6]	MITANI F, LIN JY, SAKAMOTO T, et al. Asteltoxin inhibits extracellular vesicle production through AMPK/mTOR-mediated activation of lysosome function[J]. Sci Rep, 2022, 12( 1): 6674. DOI: 10.1038/s41598-022-10692-0.
[7]	WILLMS E, CABAÑAS C, MÄGER I, et al. Extracellular vesicle heterogeneity: Subpopulations, isolation techniques, and diverse functions in cancer progression[J]. Front Immunol, 2018, 9: 738. DOI: 10.3389/fimmu.2018.00738.
[8]	SINHA D, ROY S, SAHA P, et al. Trends in research on exosomes in cancer progression and anticancer therapy[J]. Cancers, 2021, 13( 2): 326. DOI: 10.3390/cancers13020326.
[9]	PAPADAKOS SP, DEDES N, PERGARIS A, et al. Exosomes in the treatment of pancreatic cancer: A moonshot to PDAC treatment?[J]. Int J Mol Sci, 2022, 23( 7): 3620. DOI: 10.3390/ijms23073620.
[10]	ZHAO L, PEI RF, DING YR, et al. LOXL4 shuttled by tumor cells-derived extracellular vesicles promotes immune escape in hepatocellular carcinoma by activating the STAT1/PD-L1 axis[J]. J Immunother, 2024, 47( 2): 64- 76. DOI: 10.1097/CJI.0000000000000496.
[11]	MAO XW, ZHOU LY, TEY SK, et al. Tumour extracellular vesicle-derived Complement Factor H promotes tumorigenesis and metastasis by inhibiting complement-dependent cytotoxicity of tumour cells[J]. J Extracell Vesicles, 2020, 10( 1): e12031. DOI: 10.1002/jev2.12031.
[12]	YANG Y, MAO FF, GUO L, et al. Tumor cells derived-extracellular vesicles transfer miR-3129 to promote hepatocellular carcinoma metastasis by targeting TXNIP[J]. Dig Liver Dis, 2021, 53( 4): 474- 485. DOI: 10.1016/j.dld.2021.01.003.
[13]	SHIBATA C, OTSUKA M, SHIMIZU T, et al. Extracellular vesicle-mediated RNA editing may underlie the heterogeneity and spread of hepatocellular carcinoma in human tissue and in vitro[J]. Oncol Rep, 2023, 50( 5): 194. DOI: 10.3892/or.2023.8631.
[14]	MAO XW, TEY SK, YEUNG CLS, et al. Nidogen 1-enriched extracellular vesicles facilitate extrahepatic metastasis of liver cancer by activating pulmonary fibroblasts to secrete tumor necrosis factor receptor 1[J]. Adv Sci, 2020, 7( 21): 2002157. DOI: 10.1002/advs.202002157.
[15]	MEI PR, TEY SK, WONG SWK, et al. Actin-related protein 2/3 complex subunit 2-enriched extracellular vesicles drive liver cancer metastasis[J]. Hepatol Int, 2022, 16( 3): 603- 613. DOI: 10.1007/s12072-022-10338-3.
[16]	LIU BHM, TEY SK, MAO XW, et al. TPI1-reduced extracellular vesicles mediated by Rab20 downregulation promotes aerobic glycolysis to drive hepatocarcinogenesis[J]. J Extracell Vesicles, 2021, 10( 10): e12135. DOI: 10.1002/jev2.12135.
[17]	TAN WC, ZHANG JX, LIU LX, et al. Hsp90 inhibitor STA9090 induced VPS35 related extracellular vesicle release and metastasis in hepatocellular carcinoma[J]. Transl Oncol, 2022, 26: 101502. DOI: 10.1016/j.tranon.2022.101502.
[18]	SICA A, MANTOVANI A. Macrophage plasticity and polarization: in vivo veritas[J]. J Clin Invest, 2012, 122( 3): 787- 795. DOI: 10.1172/JCI59643.
[19]	PELLO OM, PIZZOL MD, MIROLO M, et al. Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology[J]. Blood, 2012, 119( 2): 411- 421. DOI: 10.1182/blood-2011-02-339911.
[20]	ARORA S, DEV K, AGARWAL B, et al. Macrophages: Their role, activation and polarization in pulmonary diseases[J]. Immunobiology, 2018, 223( 4-5): 383- 396. DOI: 10.1016/j.imbio.2017.11.001.
[21]	DENARDO DG, RUFFELL B. Macrophages as regulators of tumour immunity and immunotherapy[J]. Nat Rev Immunol, 2019, 19( 6): 369- 382. DOI: 10.1038/s41577-019-0127-6.
[22]	BOUTILIER AJ, ELSAWA SF. Macrophage polarization states in the tumor microenvironment[J]. Int J Mol Sci, 2021, 22( 13): 6995. DOI: 10.3390/ijms22136995.
[23]	DENARDO DG, BARRETO JB, ANDREU P, et al. CD4⁺ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages[J]. Cancer Cell, 2009, 16( 2): 91- 102. DOI: 10.1016/j.ccr.2009.06.018.
[24]	ZHOU JY, CHE JH, XU L, et al. Tumor-derived extracellular vesicles containing long noncoding RNA PART1 exert oncogenic effect in hepatocellular carcinoma by polarizing macrophages into M2[J]. Dig Liver Dis, 2022, 54( 4): 543- 553. DOI: 10.1016/j.dld.2021.07.005.
[25]	LV SM, WANG JH, LI L. Extracellular vesicular lncRNA FAL1 promotes hepatocellular carcinoma cell proliferation and invasion by inducing macrophage M2 polarization[J]. J Physiol Biochem, 2023, 79( 3): 669- 682. DOI: 10.1007/s13105-022-00922-4.
[26]	LI JJ, XUE JC, LING M, et al. MicroRNA-15b in extracellular vesicles from arsenite-treated macrophages promotes the progression of hepatocellular carcinomas by blocking the LATS1-mediated Hippo pathway[J]. Cancer Lett, 2021, 497: 137- 153. DOI: 10.1016/j.canlet.2020.10.023.
[27]	NING JY, YE YN, BU DC, et al. Imbalance of TGF-β1/BMP-7 pathways induced by M2-polarized macrophages promotes hepatocellular carcinoma aggressiveness[J]. Mol Ther, 2021, 29( 6): 2067- 2087. DOI: 10.1016/j.ymthe.2021.02.016.
[28]	PU J, XU ZM, NIAN JH, et al. M2 macrophage-derived extracellular vesicles facilitate CD8⁺ T cell exhaustion in hepatocellular carcinoma via the miR-21-5p/YOD1/YAP/β-catenin pathway[J]. Cell Death Discov, 2021, 7( 1): 182. DOI: 10.1038/s41420-021-00556-3.
[29]	WANG XB, YE XX, CHEN YP, et al. Mechanism of M2 type macrophage-derived extracellular vesicles regulating PD-L1 expression via the MISP/IQGAP1 axis in hepatocellular carcinoma immunotherapy resistance[J]. Int Immunopharmacol, 2023, 124( Pt A): 110848. DOI: 10.1016/j.intimp.2023.110848.
[30]	ZHANG HY, DENG T, GE SH, et al. Exosome circRNA secreted from adipocytes promotes the growth of hepatocellular carcinoma by targeting deubiquitination-related USP7[J]. Oncogene, 2019, 38( 15): 2844- 2859. DOI: 10.1038/s41388-018-0619-z.
[31]	DENG L, WANG C, HE C, et al. Bone mesenchymal stem cells derived extracellular vesicles promote TRAIL-related apoptosis of hepatocellular carcinoma cells via the delivery of microRNA-20a-3p[J]. Cancer Biomark, 2021, 30( 2): 223- 235. DOI: 10.3233/CBM-201633.
[32]	DENG J, KE H. Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles[J]. Oncoimmunology, 2023, 12( 1): 2152635. DOI: 10.1080/2162402X.2022.2152635.
[33]	BALDARI S, ROCCO GD, MAGENTA A, et al. Extracellular vesicles-encapsulated microRNA-125b produced in genetically modified mesenchymal stromal cells inhibits hepatocellular carcinoma cell proliferation[J]. Cells, 2019, 8( 12): 1560. DOI: 10.3390/cells8121560.
[34]	CABIATI M, GIORGI ND, SALVADORI C, et al. Transcriptional level evaluation of osteopontin/miRNA-181a axis in hepatocellular carcinoma cell line-secreted extracellular vesicles[J]. Pathol Res Pract, 2022, 238: 154088. DOI: 10.1016/j.prp.2022.154088.

Relative Articles

[1]	Jiarui YANG, Jianxin JIANG. An excerpt of EASL clinical practice guidelines on the management of hepatocellular carcinoma（2024 edition）[J]. Journal of Clinical Hepatology, 2025, 41(2): 234-239. doi: 10.12449/JCH250207
[2]	Lijuan LONG, Zongyu WANG, Yali ZHAO, Chuanfu QIN, Hua QIU. Research advances in traditional Chinese medicine for the treatment of hepatocellular carcinoma by regulating immune cells[J]. Journal of Clinical Hepatology, 2025, 41(2): 349-358. doi: 10.12449/JCH250223
[3]	Yuxiang GUO, Maosen WANG, Zhongyuan LIU, Xudong ZHANG, Pengfei MA, Xiangkun WANG, Renfeng LI. Advances in the diagnosis and treatment of hepatocellular carcinoma with bile duct tumor thrombus[J]. Journal of Clinical Hepatology, 2025, 41(2): 359-364. doi: 10.12449/JCH250224
[4]	Yue YANG, Siyu XU, Jue WANG, Shilin DU, Chunlei ZHANG, Haiyan SONG. Mechanism of action of cinobufotalin in inhibiting lung metastasis of hepatocellular carcinoma by regulating AKT-mediated epithelial-mesenchymal transition in a nude mouse model[J]. Journal of Clinical Hepatology, 2024, 40(9): 1840-1847. doi: 10.12449/JCH240919
[5]	Yuan DUAN, Ting ZHANG, Jing ZHANG, Guiwen GUAN, Jingzhou WANG, Xiangmei CHEN. Expression of AU-rich element RNA-binding factor 1 in hepatocellular carcinoma and its value in prognostic evaluation[J]. Journal of Clinical Hepatology, 2024, 40(9): 1833-1839. doi: 10.12449/JCH240918
[6]	Zheng SONG, Wei LUO, Xiujuan CHANG, Yongping YANG. Construction of a novel disulfidptosis-related prognostic model for patients with hepatocellular carcinoma based on bioinformatics analysis[J]. Journal of Clinical Hepatology, 2024, 40(9): 1822-1832. doi: 10.12449/JCH240917
[7]	Changwang ZHANG, Ninghan WU, Cong WANG, Zheng ZHENG, Siming GAO, Changpeng ZOU, Sujing ZHANG, Na LI. Efficacy and safety of cryoablation combined with Camrelizumab monoclonal antibody in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(6): 1169-1174. doi: 10.12449/JCH240616
[8]	Xiaohua ZHANG, Ying FENG, Xianbo WANG. Role of the Hedgehog signaling pathway in hepatocellular carcinoma and its tumor microenvironment[J]. Journal of Clinical Hepatology, 2024, 40(4): 822-827. doi: 10.12449/JCH240429
[9]	Shichun LU. Challenges and reflections on conversion therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1738-1740. doi: 10.12449/JCH240904
[10]	Chi MA, Guang TAN. Strategies and practice of conversion therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1725-1731. doi: 10.12449/JCH240902
[11]	Xiaomeng YAO, Keke SUN, Yunkai LIN, Hui WANG, Liwei DONG, Lei CHEN, Heping HU. Molecular mechanism of lenvatinib resistance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(12): 2524-2530. doi: 10.12449/JCH241225
[12]	Zhi LIU, Xiaohong DU, Wengang CHAI. Efficacy of des-γ-carboxy-prothrombin in the diagnosis of hepatocellular carcinoma and its association with the clinical features of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(10): 2014-2018. doi: 10.12449/JCH241014
[13]	Chun GAO, Jingjing JIANG, Yuchun CHEN, Xiaohui YU, Jiucong ZHANG, . Mechanism of action of N7-methylguanosine in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(12): 2946-2951. doi: 10.3969/j.issn.1001-5256.2023.12.029
[14]	Liver Oncology Branch, China Association for the Promotion of International Exchange in Healthcare, Immunology Branch. Chinese expert consensus on targeted immunotherapy combined with local therapy for advanced hepatocellular cancer[J]. Journal of Clinical Hepatology, 2023, 39(12): 2782-2792. doi: 10.3969/j.issn.1001-5256.2023.12.006
[15]	Quan ZHOU, Chunlin CAI, Jinqiang LI. Gut-liver axis： Intestinal microbial homeostasis and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2710-2717. doi: 10.3969/j.issn.1001-5256.2023.11.029
[16]	Pengwei REN, Ying HAN, Xinmin ZHOU. Predictive indicators for the efficacy of targeted therapy/immunotherapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2705-2709. doi: 10.3969/j.issn.1001-5256.2023.11.028
[17]	Zhisong NI, Junhan WEN, Weiwei ZHAO, Shoujun YU, Liang HAO, Yu CHENG, Xin LIU. Neoadjuvant therapy for hepatocellular carcinoma： Current situation and prospects[J]. Journal of Clinical Hepatology, 2023, 39(11): 2697-2704. doi: 10.3969/j.issn.1001-5256.2023.11.027
[18]	Kechun WANG, Mingda WANG, Tian YANG. Key points in AASLD Practice Guidance on Prevention， Diagnosis， and Treatment of Hepatocellular Carcinoma （2023）[J]. Journal of Clinical Hepatology, 2023, 39(9): 2081-2086. doi: 10.3969/j.issn.1001-5256.2023.09.008
[19]	Yuyan TANG, Shibin XIE, Jianyun ZHU. Diagnostic efficacy of alpha-fetoprotein and alpha-fetoprotein L3% in hepatitis B virus-related early-stage hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2607-2613. doi: 10.3969/j.issn.1001-5256.2023.11.014
[20]	Wang JiangYu, Wang ZhiXin, Fan HaiNing. Role of extracellular vesicles in the development and progression of liver diseases[J]. Journal of Clinical Hepatology, 2018, 34(3): 653-657. doi: 10.3969/j.issn.1001-5256.2018.03.048

Supplements(0)

Cited By

Cited by

Periodical cited type(1)

伍杨，李甜，张润兵，王顺娜，史婷婷，张亚妮，朱玲玲，高春，郑晓凤，张久聪. 血清学生物标志物在早期胃癌筛查中的作用研究进展. 浙江医学. 2025(01): 89-94 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(3)

Get Citation

PDF

XML

Article Metrics

Article views (276) PDF downloads(34)